


Ask a doctor about a prescription for Dexak Sl
Dexketoprofen
This medicine should always be taken exactly as described in the patient leaflet or as advised by a doctor or pharmacist.
Dexak SL is a pain-relieving medicine belonging to the group of non-steroidal anti-inflammatory drugs (NSAIDs). Dexak SL is used for the short-term, symptomatic treatment of mild to moderate acute pain, such as acute muscle or joint pain, painful menstruation, or toothache.
Before starting treatment with Dexak SL, the patient should discuss it with their doctor or pharmacist.
Dexak SL may mask the symptoms of an infection, such as fever and pain. Therefore, Dexak SL may delay the use of appropriate infection treatment, which can lead to increased risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If the patient is taking this medicine during an infection and the symptoms of the infection persist or worsen, they should immediately consult their doctor. The patient should avoid taking this medicine during chickenpox.
The use of this medicine in children and adolescents has not been studied. The safety and efficacy of this medicine have not been established, and therefore, it should not be used in children and adolescents.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. Some medicines should not be taken at the same time as Dexak SL, and in the case of other medicines, the dose may need to be changed when taken with Dexak SL. The patient should always inform their doctor, dentist, or pharmacist if they are taking any of the following medicines with Dexak SL:
Concomitant use that requires caution:
Concomitant use that requires special consideration:
In case of any doubts about taking Dexak SL, the patient should consult their doctor or pharmacist.
In case of acute pain, it is recommended to take the medicine on an empty stomach, e.g., at least 15 minutes before a meal, which will allow the medicine to start working faster.
Dexak SL should not be taken during the last three months of pregnancy or during breastfeeding. If the patient is pregnant, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine, as the use of Dexak SL may be inappropriate in this situation. Women who are pregnant or planning to become pregnant should avoid taking this medicine. The use of Dexak SL during pregnancy should only be done under the doctor's recommendation. Dexak SL is not recommended for women planning pregnancy or undergoing fertility treatment. Information on the potential impact on fertility can be found in section 2, "Warnings and precautions".
Dexak SL may have a minor impact on the ability to drive vehicles and operate machinery, as it may cause dizziness and vision disturbances. If such symptoms are observed, the patient should not drive vehicles or operate machinery in motion until the symptoms resolve. In case of doubts, the patient should consult their doctor.
If the doctor has informed the patient that they have an intolerance to some sugars, they should consult their doctor before taking the medicine. Each dose contains 2.418 g of sucrose. This should also be taken into account in patients with diabetes.
This medicine should always be taken exactly as described in the patient leaflet or as advised by a doctor or pharmacist. In case of doubts, the patient should consult their doctor or pharmacist. The patient should use the smallest effective dose for the shortest duration necessary to relieve symptoms. If the symptoms of an infection (such as fever and pain) persist or worsen, the patient should immediately consult their doctor (see section 2). Adults over 18 yearsThe recommended daily dose is 1 sachet (25 mg) every 8 hours, but no more than 3 sachets per day (75 mg). If after 3 to 4 days there is no improvement or the patient feels worse, they should contact their doctor. The doctor will inform the patient how many sachets to take per day and for how long. The dose of Dexak SL will depend on the type, severity, and duration of the pain in the patient. In elderly patients or those with kidney or liver disease, it is recommended to start treatment with a lower total daily dose, not exceeding 2 sachets (50 mg). In elderly patients with good tolerance, this initial dose can be increased to the recommended dose for the general population (75 mg of dexketoprofen). In case of acute pain, when faster relief is needed, it is recommended to take the medicine on an empty stomach (at least 15 minutes before a meal), which will cause faster absorption of the medicine (see section 2, "Dexak SL with food and drink"). Children and adolescentsThis medicine should not be used in children and adolescents (under 18 years).
The contents of the sachet should be dissolved in a glass of water and well mixed to facilitate dissolution. The resulting solution should be taken immediately after preparation.
In case of suspected overdose, the patient should inform their doctor or pharmacist or go to the nearest hospital emergency department. The patient should remember to take the medicine packaging or patient leaflet with them.
The patient should not take a double dose to make up for a missed dose. The next dose should be taken according to the dosing schedule (see section 3, "How to take Dexak SL"). In case of any further doubts about taking Dexak SL, the patient should consult their doctor or pharmacist.
Like all medicines, Dexak SL can cause side effects, although not everybody gets them. Possible side effects are listed below and are grouped according to the frequency of their occurrence. The information provided is partly based on data on side effects for Dexak tablets, and since Dexak SL granules are absorbed faster than tablets, the frequency of side effects related to the gastrointestinal system may be higher.
Nausea and/or vomiting, abdominal pain, mainly in the upper quadrants, diarrhea, indigestion (dyspepsia).
Vertigo of labyrinthine origin, dizziness, drowsiness, sleep disturbances, nervousness, headaches, palpitations, facial flushing, gastritis (gastric inflammation), constipation, dry mouth, bloating, rash, fatigue, pain, feeling of fever and chills, malaise.
Gastric ulcer, bleeding, or perforation of the digestive tract, which may manifest as bloody vomiting or black stools, fainting, high blood pressure, slowed breathing rate, fluid retention and peripheral edema (e.g., swollen ankles), laryngeal edema, loss of appetite (anorexia), abnormal sensation, pruritic rash, acne, increased sweating, back pain, increased urination, menstrual disorders, prostate disorders, abnormal liver function tests (blood tests), liver cell damage (hepatitis), acute kidney failure.
Anaphylactic reactions (acute hypersensitivity reactions that can lead to anaphylactic shock), skin ulcers, mouth, eye, and genital ulcers (Stevens-Johnson syndrome and Lyell syndrome), facial edema or lip and throat edema (angioedema), shortness of breath due to bronchial constriction (bronchospasm), shortness of breath, rapid heart rate, low blood pressure, pancreatitis, blurred vision, tinnitus (ringing in the ears), skin hypersensitivity reactions, skin hypersensitivity to light, itching, kidney problems, decreased white blood cell count (neutropenia), decreased platelet count (thrombocytopenia). The patient should immediately inform their doctor if they notice any side effects related to the stomach or intestines (e.g., stomach pain, heartburn, or bleeding) at the beginning of treatment, especially if they have had similar side effects in the past due to long-term use of anti-inflammatory medicines, particularly in elderly patients. If a skin rash or any damage to the mucous membranes inside the mouth or on the genitals or any symptoms of allergy occur, the patient should stop treatment with Dexak SL immediately. During the administration of non-steroidal anti-inflammatory drugs, fluid retention and edema (especially of the ankles and feet) may occur, as well as increased blood pressure and heart failure. Taking such medications as Dexak SL may be associated with a slight increase in the risk of heart attack or stroke. In patients with systemic lupus erythematosus or mixed connective tissue disease (immune system disorders affecting connective tissue), the administration of anti-inflammatory medicines may rarely cause fever, headache, and neck stiffness. The most commonly observed side effects were related to the stomach and intestines. Especially in elderly patients, gastric ulcers, perforation, or bleeding from the stomach and/or duodenum may occur, in some cases with fatal outcomes. After the use of the medicine, the following were observed: nausea, vomiting, diarrhea, bloating, constipation, indigestion, abdominal pain, black stools, bloody vomiting, mouth ulcers, exacerbation of colitis, and Crohn's disease. Less frequently, gastritis was observed. As with other NSAIDs, hematologic reactions (thrombocytopenia, aplastic anemia, and hemolytic anemia, rarely agranulocytosis, and bone marrow hypoplasia) may occur.
If side effects occur, including any side effects not listed in the leaflet, the patient should tell their doctor or pharmacist or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the carton and sachet. The expiry date refers to the last day of the month. There are no special precautions for storage of the medicinal product. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Sachets containing yellowish granules. Dexak SL is available in packs of 10, 20, or 30 sachets. Not all pack sizes may be marketed.
Berlin-Chemie AG, Glienicker Weg 125, 12489 Berlin, Germany
LABORATORIOS MENARINI S.A., C/ Alfons XII 587, 08918-Badalona (Barcelona), Spain This medicinal product is authorized in the Member States of the European Economic Area under the following names: Austria, Belgium, France, Italy, Luxembourg, Portugal, Spain: Ketesse Cyprus, Greece: Nosatel Czech Republic: Dexoket Estonia, Latvia, Lithuania: Dolmen Germany: Sympal Hungary: Ketodex Ireland, Malta, United Kingdom (Northern Ireland): Keral Netherlands: Stadium Poland: Dexak SL Slovakia: Dexadol Slovenia: Menadex For more information, the patient should contact their local representative of the marketing authorization holder: Berlin-Chemie/Menarini Polska Sp. z o.o., Tel. (22) 566 21 00, Fax (22) 566 21 01 Date of last revision of the leaflet: 12/2021
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Dexak Sl – subject to medical assessment and local rules.